This is a multi-center, prospective, non-interventional cohort study .
Its primary objectives are:
1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice;
2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of DILI patients with various types and severity according to the 2015 version of the Chinese DILI treatment guidelines
* RUCAM ≥6, or RUCAM between 3-5 is required by the three experts determined that the drug-induced liver injury
* patient can provide informed consent form
Exclusion Criteria:
* non-drug-induced liver injury
Primary outcome measure(s)
Disease progression of DILI (drug-induced liver injury ), i.e. death, liver failure, chronic DILI, recover — 6 months
Trial sites (1)
Facility
City
Region
Status
Renji hospital
Shanghai
China
Recruiting
More Drug Induced Liver Disease Study Group trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.